In a recent “Letter to the Editor” published in the English edition of the journal Neurology, researchers reported the rare occurrence of Hashimoto’s encephalopathy in a Spikevax (COVID-19) vaccine recipient. Spikevax, the studies call mRNA-1273, is a COVID-19 vaccine in messenger ribonucleic acid (mRNA) technology.
Antithyroid antibodies are provided in 13% of healthy people. In rare cases, it triggers an autoimmune encephalopathy, known as Hashimoto’s encephalopathy. The underlying pathophysiology of this disease is unclear, the pathogenicity of antithyroid antibodies.
Studies have shown that some vaccines worsen immune-mediated neurological diseases. For example, vaccines against influenza, measles, mumps, rubella, and hepatitis B caused 708 cases of autoimmune encephalitis in the United States between 1990 and 2010. However, its relationship to vaccines remains debatable and has no causal relationship.
Under its Emergency Use Authorization (EUA), 11 billion doses of COVID-19 vaccines have been administered worldwide. Although the onset of Hashimoto’s encephalopathy is rare (less than one case consistent with millions of patients) after vaccination, it is conceivable that vaccination unlike COVID-19 may cause it. In addition, several cases of post-vaccine encephalitis have been reported in recipients of COVID-19 vaccines, based on mRNA and viral vectors.
In addition, studies reported neurological headaches after vaccination after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For example, the U. S. Centers for Disease Control and Prevention has been in the U. S. Centers for Disease Control and Prevention. The U. S. Department of Health (US-CDC) reported cases of Guillain-Barré in recipients of the Ad26. COV2. S adenoviral vector-based vaccine. The European Medicines Agency (EMA) has reported cases of acute disseminated encephalomyelitis and encephalitis in ChAdOx1 receptors. These neurological headaches appear to be less unusual with mRNA vaccines than with adenovirus vaccines.
In the existing study, the researchers presented one of the first cases of Hashimoto’s encephalopathy as a very likely complication of SARS-CoV-2 vaccination. A 36-year-old man met Graus’ criteria, had antithyroid antibodies in the cerebrospinal fluid (CSF). ). In addition, he presented the typical guyifestaciones of encephalopathy.
The patient had a history of autoimmune hypothyroidism but no psychiatric disorders. He won the first dose of the Spikevax vaccine in July 2021 and his dose so far 28 days later. Within 24 hours of receiving the current vaccine, he presented with a self-limited febrile syndrome and mild postural tremors. Six days later he presented a first focal seizure in the left hemisphere, evolving to bilateral tonic-clonic seizures and convulsive prestige epilepticus. He was immediately admitted to the intensive care unit (ICU).
A computed tomography (CT) scan and CT angiography examination showed a vascular or neoplastic etiology. However, an electroencephalogram (EEG) showed symmetrical diffuse deceleration. On brain magnetic resonance imaging (MRI), diffusion sequences revealed cortical hyperintensity at the left temporal pole, attributed to alterations in postcritical signaling.
Polymerase chain reaction (PCR) tests for neurotropic viruses were negative. CSF studies showed elevated protein levels (98 mg/dL) but a mobile count within the overall range. Initially, the serum did not contain antineuronal antibodies; PCR for SARS-CoV-2 was negative at baseline and in all subsequent tests. In addition, the researchers did not notice any pathological disorders in the blood test, adding biochemistry, complete blood count, kidney and liver function, etc.
The patient suffered a momentary episode of tonic seizure in November 2021 and was readmitted to intensive care. In addition to higher postural tremors, difficulty walking and memory deficits (Montreal Cognitive Assessment [MoCA] score of 21/30). Doctors prescribed a short course of methylprednisolone.
After partial improvement, ultrasound examination revealed a general thyroid morphology, the patient had ATG and TPO antibody levels of 4. 2 IU/L and 60. 9 IU/L in the CSF. An earlier CSF study showed overall levels of IgG and ADA antibodies, and effects for antineuronal antibodies were negative.
In addition, their thyroid-stimulating hormone levels, T4 and T3 were 4. 4 mIU/L, 1. 0 nmol/L, and 2. 7 nmol/L, respectively. Serum investigation revealed thyroglobulin (TGA) and thyroididase-peroxidase (TPO) antibody levels of 986 IU/L and 538 IU/L, respectively. Fortunately, the patient also had no malignancy on CT scans of the chest, stomach, or pelvis. Doctors gave him the momentary course of methylprednisolone, which reduced tremors and accelerated his gait. He continued with the prescribed maintenance remedy with prednisone at discharge. Within six months, he had had no seizures and could walk independently, with a MoCA score of 27/30.
An underlying molecular mimicry with the SARS-CoV-2 spike protein that affects the loss of the maximum maximum transmembrane anchorage of this protein likely triggers adverse events, such as Hashimoto’s encephalopathy. However, the occurrence of Hashimoto’s encephalopathy is about 617 times lower than that. caused through an herbal viral infection. Therefore, the benefits of the COVID-19 vaccine or any other vaccine obviously outweigh the dangers of vaccination.
Written By
Neha is a virtual marketing professional founded in Gurugram, India. He holds a master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. He has enjoyed preclinical studies as part of his assignment of studies in Toxicology Decomposition from the prestigious Central Drug Research Institute (CDRI), Lucknow, India. He also holds a certification in C programming.
Use one of the following to cite this article in your essay, article, or report:
ap
Mathur, Neha. (2022, October 16). A case of Hashimoto’s encephalopathy after COVID vaccination. Actus-Médicale. Retrieved on October 23, 2022, from https://www. news-medical. net/news/20221016/A–case-of-Hashimoto-encephalopathy-after- COVID-vaccination. aspx.
deputy
Mathur, Neha. ” A case of Hashimoto’s encephalopathy after COVID vaccination. “News-Medical. October 23, 2022.
Chicago
Mathur, Neha. ” A case of Hashimoto’s encephalopathy after COVID vaccination. “. . aspx. (accessed October 23, 2022).
Harvard
Mathur, Neha. 2022. A case of Hashimoto’s encephalopathy after COVID vaccination. News-Medical, accessed 23 October 2022, https://www. news-medical. net/news/20221016/A–case-of-Hashimoto- encephalopathy-after-vaccination-COVID. aspx.
News-Medical. net – An AZoNetwork website
Owned and operated through AZoNetwork, © 2000-2022